A citation-based method for searching scientific literature

John A D'Elia, Alissa R Segal, George P Bayliss, Larry A Weinrauch. Int J Nephrol Renovasc Dis 2017
Times Cited: 7







List of co-cited articles
29 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
57

Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition.
Anne L Peters, Elizabeth O Buschur, John B Buse, Pejman Cohan, Jamie C Diner, Irl B Hirsch. Diabetes Care 2015
433
57

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
42

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
42

Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program.
Ngozi Erondu, Mehul Desai, Kirk Ways, Gary Meininger. Diabetes Care 2015
202
42

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.
Ele Ferrannini, Elza Muscelli, Silvia Frascerra, Simona Baldi, Andrea Mari, Tim Heise, Uli C Broedl, Hans-Juergen Woerle. J Clin Invest 2014
634
42

Euglycaemic diabetic ketoacidosis.
J F Munro, I W Campbell, A C McCuish, L J Duncan. Br Med J 1973
155
42

SGLT2 Inhibitors May Predispose to Ketoacidosis.
Simeon I Taylor, Jenny E Blau, Kristina I Rother. J Clin Endocrinol Metab 2015
268
42

Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor.
Michael Fralick, Sebastian Schneeweiss, Elisabetta Patorno. N Engl J Med 2017
146
42

Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.
Steven P Marso, Darren K McGuire, Bernard Zinman, Neil R Poulter, Scott S Emerson, Thomas R Pieber, Richard E Pratley, Poul-Martin Haahr, Martin Lange, Kirstine Brown-Frandsen,[...]. N Engl J Med 2017
290
28

SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System.
Gian Paolo Fadini, Angelo Avogaro. Lancet Diabetes Endocrinol 2017
83
28


SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System.
Gian Paolo Fadini, Benedetta Maria Bonora, Angelo Avogaro. Diabetologia 2017
105
28

Sodium-Glucose Cotransporter 2 Inhibitors and Diabetic Ketoacidosis: A Case Series From Three Academic Institutions.
Negin Misaghian-Xanthos, Afreen I Shariff, Kavya Mekala, Loretta R Fearrington, Tracy L Setji, Joseph A Aloi, John B Buse. Diabetes Care 2017
9
28


Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.
Aurora Merovci, Carolina Solis-Herrera, Giuseppe Daniele, Roy Eldor, Teresa Vanessa Fiorentino, Devjit Tripathy, Juan Xiong, Zandra Perez, Luke Norton, Muhammad A Abdul-Ghani,[...]. J Clin Invest 2014
477
28

Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
Ele Ferrannini, Simona Baldi, Silvia Frascerra, Brenno Astiarraga, Tim Heise, Roberto Bizzotto, Andrea Mari, Thomas R Pieber, Elza Muscelli. Diabetes 2016
283
28

Renal, metabolic and cardiovascular considerations of SGLT2 inhibition.
Ralph A DeFronzo, Luke Norton, Muhammad Abdul-Ghani. Nat Rev Nephrol 2017
213
28


Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data.
Jenny E Blau, Sri Harsha Tella, Simeon I Taylor, Kristina I Rother. Diabetes Metab Res Rev 2017
81
28

SGLT inhibition and euglycaemic diabetic ketoacidosis.
Julia Hine, Heather Paterson, Esha Abrol, David Russell-Jones, Roselle Herring. Lancet Diabetes Endocrinol 2015
55
28

Euglycemic Diabetic Ketoacidosis: A Review.
Anar Modi, Abhinav Agrawal, Farah Morgan. Curr Diabetes Rev 2017
68
28

Prolonged Ketosis in a Patient With Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin.
Shreya Pujara, Adriana Ioachimescu. J Investig Med High Impact Case Rep 2017
17
28

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
28

Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study.
Peter Ueda, Henrik Svanström, Mads Melbye, Björn Eliasson, Ann-Marie Svensson, Stefan Franzén, Soffia Gudbjörnsdottir, Kristian Hveem, Christian Jonasson, Björn Pasternak. BMJ 2018
145
28



SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.
Kelly R Burke, Christine A Schumacher, Spencer E Harpe. Pharmacotherapy 2017
91
28

Dehydration and insulinopenia are necessary and sufficient for euglycemic ketoacidosis in SGLT2 inhibitor-treated rats.
Rachel J Perry, Aviva Rabin-Court, Joongyu D Song, Rebecca L Cardone, Yongliang Wang, Richard G Kibbey, Gerald I Shulman. Nat Commun 2019
38
28


Ipragliflozin Reduces Epicardial Fat Accumulation in Non-Obese Type 2 Diabetic Patients with Visceral Obesity: A Pilot Study.
Tatsuya Fukuda, Ryotaro Bouchi, Masahiro Terashima, Yuriko Sasahara, Masahiro Asakawa, Takato Takeuchi, Yujiro Nakano, Masanori Murakami, Isao Minami, Hajime Izumiyama,[...]. Diabetes Ther 2017
47
14


LAPS Insulin115: A novel ultra-long-acting basal insulin with a unique action profile.
Nina Wronkowitz, Thorsten Hartmann, Sven Wolfgang Görgens, Daniela Dietze-Schroeder, Ira Indrakusuma, In Young Choi, Sung Hee Park, Young-Mi Lee, Se Chang Kwon, Yeonjoo Kang,[...]. Diabetes Obes Metab 2017
17
14

Inhaled Insulin: A Clinical and Historical Review.
Jason Chan, Angela Cheng-Lai. Cardiol Rev 2017
6
16



Prediction of 10-year vascular risk in patients with diabetes: the AD-ON risk score.
M Woodward, Y Hirakawa, A-P Kengne, D R Matthews, S Zoungas, A Patel, N Poulter, R Grobbee, M Cooper, M Jardine,[...]. Diabetes Obes Metab 2016
18
14

A novel option for prandial insulin therapy: inhaled insulin.
George Dailey, Aakif Ahmad, Sarit Polsky, Viral Shah. Postgrad Med 2016
4
25

A Fixed Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Reduces Glycemic Fluctuation and Brings More Patients with Type 2 Diabetes Within Blood Glucose Target Ranges.
Allen B King, Athena Philis-Tsimikas, Eric S Kilpatrick, Irene H Langbakke, Kamilla Begtrup, Tina Vilsbøll. Diabetes Technol Ther 2017
12
14


A randomized clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 1.
S Garg, M Dreyer, H Jinnouchi, J Mou, Y Qu, M L Hartman, M Rosilio, S J Jacober, E J Bastyr. Diabetes Obes Metab 2016
23
14

Efficacy of Additional Canagliflozin Administration to Type 2 Diabetes Patients Receiving Insulin Therapy: Examination of Diurnal Glycemic Patterns Using Continuous Glucose Monitoring (CGM).
Mihoko Matsumura, Yuki Nakatani, Seiichi Tanka, Chie Aoki, Masaaki Sagara, Kazunori Yanagi, Kunihiro Suzuki, Yoshimasa Aso. Diabetes Ther 2017
28
14


Pharmacokinetic and Pharmacodynamic Properties of a Novel Inhaled Insulin.
Lutz Heinemann, Robert Baughman, Anders Boss, Marcus Hompesch. J Diabetes Sci Technol 2017
32
14

Effect of insulin degludec versus insulin glargine on glycemic control and daily fasting blood glucose variability in insulin-naïve Japanese patients with type 2 diabetes: I'D GOT trial.
Yoshimasa Aso, Kunihiro Suzuki, Yasuko Chiba, Minoru Sato, Nobuya Fujita, Yoshihisa Takada, Shunichi Murano, Hisamoto Kuroda. Diabetes Res Clin Pract 2017
14
14



Efficacy and Safety of Insulin Degludec for Hyperglycemia Management in Noncritical Hospitalized Patients with Diabetes: An Observational Study.
Natalino Simioni, Alessio Filippi, Marco Scardapane, Antonio Nicolucci, Maria Chiara Rossi, Vera Frison. Diabetes Ther 2017
5
20




Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.